SCHEMBL1906186

SCHEMBL1906186

Cc1ccc(S(=O)(=O)O)c(CS(=O)(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.39
HSD17B10 Q99714 2/20 0.39
KMT2A Q03164 3/20 0.36
MEP1B Q16820 2/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
RECQL P46063 1/20 0.36
CASP6 P55212 1/20 0.36
ELAVL1 Q15717 1/20 0.36
MYC P01106 1/20 0.36
RAPGEF4 Q8WZA2 1/20 0.36
MPL P40238 1/20 0.35
AMY1A P0DUB6 1/20 0.34
SNCA P37840 2/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14991279 0.85 AMY1A (0.44) GAAHSD17B10KMT2AMEP1BMEN1
SCHEMBL30236538 0.85 RAPGEF4 (0.44) GAAHSD17B10KMT2AMEP1BMEN1
SCHEMBL30716894 0.85 AMY1A (0.44) GAAHSD17B10KMT2AMEP1BMEN1
SCHEMBL30823619 0.85 GAA (0.41) GAAHSD17B10KMT2AMEP1BMEN1
SCHEMBL1180196 0.85 GAA (0.41) GAAHSD17B10KMT2AMEP1BMEN1
SCHEMBL1607815 0.85 RAPGEF4 (0.44) GAAHSD17B10KMT2AMEP1BMEN1
SCHEMBL1806437 0.83 MPL (0.38) GAAHSD17B10KMT2AMEP1BMEN1
Water SCHEMBL27145442 0.83 RAPGEF4 (0.43) GAAHSD17B10KMT2AMEP1BMEN1
SCHEMBL1806434 0.83 ALDH1A1 (0.37) GAAHSD17B10KMT2AMEP1BMEN1
SCHEMBL5718625 0.81 GAA (0.39) GAAHSD17B10KMT2AMEP1BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021110306-A1 MULTI-TONE HAIR DYEING METHOD IN THREE STEPS HENKEL AG & CO. KGAA (DE) 2021-06-10 WO disclosed
US-20150290127-A1 TRANEXAMIC ACID FORMULATIONS AMRING PHARMACEUTICALS, INC. 2015-10-15 US disclosed
US-9060939-B2 Tranexamic acid formulations FERRING B.V. (NL) 2015-06-23 US disclosed
US-8968777-B2 Tranexamic acid formulations with reduced adverse effects FERRING B.V. (NL) 2015-03-03 US disclosed
US-8957113-B2 Tranexamic acid formulations FERRING B.V. (NL) 2015-02-17 US disclosed
US-8809394-B2 Tranexamic acid formulations FERRING B.V. (NL) 2014-08-19 US disclosed
US-8791160-B2 Tranexamic acid formulations FERRING B.V. (NL) 2014-07-29 US disclosed
US-8487005-B2 Tranexamic acid formulations FERRING B.V. (NL) 2013-07-16 US disclosed
US-20130096198-A1 Tranexamic Acid Formulations FERRING B.V. (NL) 2013-04-18 US disclosed
US-20130018100-A1 Tranexamic Acid Formulations FERRING B.V. (NL) 2013-01-17 US disclosed
US-7473280-B2 Coloring agent compositions and methods of treating keratin fibers therewith HENKEL KGAA (DE) 2009-01-06 US disclosed
US-20080280981-A1 Tranexamic acid formulations XANODYNE PHARMACEUTICALS, INC. (US) 2008-11-13 US disclosed
US-20080189877-A1 Mixture of quaternized imidazo[1,5-a]pyrimidinium derivate and benzaldehyde derivative; cationic hair dyes, oxidation color dyes; colorfastness, washfastness HENKEL KGAA (DE) 2008-08-14 US disclosed
US-7393367-B2 Agent for dyeing keratin-based fibers HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2008-07-01 US disclosed
US-20080104772-A1 AGENT FOR DYEING KERATIN-BASED FIBERS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2008-05-08 US disclosed
US-20060127476-A1 Delayed release oral dosage for side effect reduction of nausea, headache; improve patient compliance in treating menorrhagia; prevents a bolus release of tranexamic acid in the stomach XANODYNE PHARMACEUTICALS, INC. (US) 2006-06-15 US disclosed
WO-2006023001-A1 TRANEXAMIC ACID FORMULATIONS XANODYNE PHARMACEUTICALS, INC. (US) 2006-03-02 WO disclosed
WO-2006023000-A1 TRANEXAMIC ACID FORMULATIONS XANODYNE PHARMACEUTICALS, INC. (US) 2006-03-02 WO disclosed
US-20050244495-A1 Adjusting release profile; urogenital disorders; blood disorders; edema XANODYNE PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
US-20050245614-A1 Oral administering; controlling blood concentration; urogenital disorders; blood disorders XANODYNE PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080104772-A1 AGENT FOR DYEING KERATIN-BASED FIBERS KRT18, KAT5, H1-5 GAA 4691/4885HSD17B10 466/4885KMT2A 2567/4885
US-20080189877-A1 Mixture of quaternized imidazo[1,5-a]pyrimidinium derivate and benzaldehyde derivative; cationic hair dyes, oxidation color dyes; colorfastness, washfastness TYR, NDUFS5, WASHC5 GAA 3840/4885HSD17B10 2529/4885KMT2A 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.